Diagnostic and Treatment Approach for Pharyngeal STIs

Diagnostic Considerations

The Centers for Disease Control and Prevention recommends culture as the most widely available and recommended diagnostic method for detecting gonorrhea and chlamydia in the pharynx, as nucleic acid amplification tests (NAATs) are not FDA-cleared for pharyngeal specimens and may cross-react with commensal Neisseria species commonly found in the throat 1, 2, 3
Gram stain is insufficient for pharyngeal specimens and should not be used for diagnosis, as it lacks adequate sensitivity and specificity for detecting infection at this site 1, 4, 5
NAATs have limitations for pharyngeal testing: while some laboratories have validated NAATs for pharyngeal swabs after meeting CLIA requirements, these tests can cross-react with nongonococcal Neisseria and related organisms naturally present in the throat 1, 2, 3

The Centers for Disease Control and Prevention recommends that all patients tested for pharyngeal gonorrhea or chlamydia must be tested for other STIs, including genital gonorrhea, chlamydia, syphilis, and HIV 1, 2, 3
Sexual history determines testing sites: assess specific sexual practices to identify all anatomical sites requiring testing (genital, rectal, pharyngeal) 6, 7
Men who have sex with men (MSM) require pharyngeal and rectal testing based on sexual practices, as extragenital infections are common in this population 6

The Centers for Disease Control and Prevention recommends dual therapy for chlamydia co-infection: if chlamydia test results are unavailable or if using a non-NAAT test that was negative, treat empirically for both infections 1, 8, 3, 7
The preferred chlamydia treatment is doxycycline 100 mg orally twice daily for 7 days 9
Alternative chlamydia treatment is azithromycin 1 g orally as a single dose, though doxycycline is preferred 9
Avoid quinolones: do not use fluoroquinolones (ciprofloxacin, ofloxacin) for gonorrhea treatment without confirmed susceptibility due to widespread resistance 8, 4, 3, 7

The Centers for Disease Control and Prevention recommends that all sexual partners from the preceding 60 days must be evaluated, tested, and treated empirically for both gonorrhea and chlamydia 9, 7
Retest at 3 months: all patients diagnosed with gonorrhea or chlamydia should be retested approximately 3 months after treatment due to high reinfection rates (regardless of whether partners were treated) 9, 7
Partners should abstain from sexual intercourse until both patient and all partners have completed treatment and are asymptomatic 7